Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer.

ABSTRACT:

Background

Even with contemporary treatment strategies, more than 10% of HER2-positive early stage breast cancer patients may experience distant metastasis as first event during follow-up. Tools for predicting unique patterns of metastatic spread are needed to plan personalized surveillance. We evaluated how molecular heterogeneity affects the pattern of distant relapse in HER2-positive breast cancer.

Methods

A total of 677 HER2-positive stage I-III breast cancer patients from ShortHER trial, Cher-LOB trial, and 2 institutional cohorts were included. PAM50 molecular subtypes and research-based HER2DX scores were evaluated. The cumulative incidence of distant relapse as the first event (any site and site specific) was evaluated using competing risk analysis. Median follow-up

SUBMITTER: Dieci MV 

PROVIDER: S-EPMC10777675 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature